1 / 4

Mimivax’s SurVaxM Improves Survival Time In Newly Diagnosed Glioblastoma

Mimivax presented encouraging findings from u201cSURVIVEu201d (Phase II a) study in patients with newly diagnosed glioblastoma (Abstract #2037)<br><br>Read More- https://www.delveinsight.com/asco-conference/article/mimivaxs-survaxm?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage

yashb
Download Presentation

Mimivax’s SurVaxM Improves Survival Time In Newly Diagnosed Glioblastoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Newly Diagnosed Newly Diagnosed Glioblastoma Glioblastoma 27.06.2022 27.06.2022 Mimivax’s SurVaxM Improves Survival Time In Newly Diagnosed Glioblastoma SurVaxM Highlights: ASCO 2022 Positive results from the "SURVIVE" (Phase II a) research in people with newly discovered glioblastoma were given by Mimivax (Abstract #2037). SurVaxM mechanism of action: Immunostimulants A cell-survival protein found in 95 percent of glioblastomas and many other malignancies, survivin is the target of SurVaxM (MimiVax), a first-in-class, proprietary peptide mimic immunogen. The SurVaxM immunotherapy for newly diagnosed glioblastoma Phase IIa (Survive) results was presented at ASCO 2022. A total of 63 patients with freshly diagnosed glioblastoma participated in the single-arm Survive research, with a median age of 60 for those who had just undergone their first round of chemoradiation. Each patient had a craniotomy, radiation therapy, and temozolomide treatment prior to receiving the SurVaxM priming dosages. It's interesting to note that, overall, 41 percent of patients survived for at least three years after receiving a glioblastoma diagnosis and 51 percent did so for at least two years. According to the study, patients NEWLY DIAGNOSED GLIOBLASTOMA 27.06.2022

  2. Newly Diagnosed Newly Diagnosed Glioblastoma Glioblastoma 27.06.2022 27.06.2022 receiving standard therapy do have a 16-month median chance of survival, and the patient did well with the immunotherapy plus temozolomide. Giving people with glioblastoma greater survival is always a step in the right direction for such a rare but fatal malignancy. "It is really encouraging to see that many patients had their tumors respond to the combination of SurVaxM and temozolomide," We're thrilled to see this encouraging treatment advance to broader studies and research into possible uses or illness situations in other settings. - Expert Verdict. Conclusion We anticipate a shift in the standard of care for patients with newly diagnosed glioblastoma from a monotemozolimide regimen to a combination regimen in light of the positive results of the SurvaxM ASCO 2022 trial. Additionally, SurvaxM might provide a higher standard of living and longer survival. Other medications, such as paxalisib (Kazia Therapeutics), Efflorithine+Lomustine (Orbus), regorafenib (Bayer), and many others are also being studied for GBM. Get in touch with our Business Expert @Business Consulting Services | Biotech Consulting | Technical Due Diligence Firms Trending & Popular Market Research Reports 2022 by Delveinsight Bag3-related Gene Therapies Market Bag3-related Gene Therapies Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Bag3- related Gene Therapies, forecasted epidemiology Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Insights, Market Forecast report delivers an understanding of the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Pediatric Growth Hormone Deficiency PGHD Market NEWLY DIAGNOSED GLIOBLASTOMA 27.06.2022

  3. Newly Diagnosed Newly Diagnosed Glioblastoma Glioblastoma 27.06.2022 27.06.2022 Pediatric Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast report delivers an understanding of the Pediatric Growth Hormone Deficiency forecasted epidemiology. SGLT2 inhibitors Market DelveInsight's SGLT2 inhibitors Market Insights, Epidemiology, and Market Forecast report delivers an in-depth understanding of the SGLT2 inhibitors, historical and forecasted epidemiology Reactive Airway Disease Market Reactive Airway Disease Market report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends in the 7MM. Carbapenem-resistant Enterobacteriaceae Infection Market Carbapenem-resistant Enterobacteriaceae Infection Market Size, Insights report delivers an understanding of the Carbapenem-resistant Enterobacteriaceae Infection forecasted epidemiology Oncolytic Virus Cancer Therapy Pipeline "Oncolytic Virus Cancer Therapy" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. Tuberculosis Market DelveInsight's Tuberculosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Tuberculosis, historical and forecasted epidemiology Testicular Neoplasm Market DelveInsight's Testicular Neoplasm Market Insights, Epidemiology, and Market Forecast report delivers an understanding forecasted epidemiology and the Testicular Neoplasm market trends in 7MM Stem Cell Market NEWLY DIAGNOSED GLIOBLASTOMA 27.06.2022

  4. Newly Diagnosed Newly Diagnosed Glioblastoma Glioblastoma 27.06.2022 27.06.2022 Stem Cell Market Research Report provides comprehensive insights into the Stem Cell Market Size, Share, Key Companies, Competitive Analysis as well as the Market Forecast Surgical Mask & Respirator Market Surgical Mask & Respirator Market Research Report provides comprehensive insights into the Surgical Mask & Respirator Market Size, Share, Key Companies, Competitive Analysis. Medical Marijuana Market DelveInsight's "Medical Marijuana Market Report 2032" offers an in-depth understanding of the Medical Marijuana epidemiology, pipeline, and market trends in the 7MM. Hepatic Cirrhosis Market DelveInsight's Hepatic Cirrhosis Market Insights, Epidemiology, and Market Forecast report delivers an in-depth understanding of the Hepatic Cirrhosis, historical and forecasted epidemiology About ASCO 2022 Conference Updates asco 2021 highlights | asco highlights 2021 | asco medical conference | asco 2021 | asco 2021 conference | when is asco 2021 | 2021 asco | 2021 asco annual meeting | asco convention | asco conference 2021 | asco 2021 | asco 21 | asco us | asco 2022 annual meeting | asco abstract 2022 About Us DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions. Contact Us Yash info@delveinsight.com NEWLY DIAGNOSED GLIOBLASTOMA 27.06.2022

More Related